Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting MinutesZervimesine is on track to become the initial long-lasting, reliable treatment option showing significant effects on the root disease. The company is working on creating NPI as a gauge for DLB psychosis.
